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Abstract
Background: Idiopathic recurrent miscarriage is defined as 3 consecutive pregnancy losses with
no contributing features found on investigations. At present there are no treatments of proven
efficacy for idiopathic recurrent miscarriage. Uterine natural killer (uNK) cells, the most
predominant leucocyte in the endometrium are adjacent to foetal trophoblast cells and thought to
be involved in implantation. The exact mechanisms of how uNK cells affect implantation are not
clear but are probably through the regulation of angiogenesis. Multiple studies have shown an
association between high density of uterine natural killer cells and recurrent miscarriage. We have
shown that prednisolone reduces the number of uNK cells in the endometrium. The question
remains as to whether reducing the number of uNK cells improves pregnancy outcome.
Methods: We propose a randomised, double-blind, placebo controlled trial of prednisolone with
a pilot phase to assess feasibility of recruitment, integrity of trial procedures, and to generate data
to base future power calculations. The primary aim is to investigate whether prednisolone therapy
during the first trimester of pregnancy is able to improve live birth rates in patients with idiopathic
recurrent miscarriage and raised uNK cells in the endometrium. Secondary outcomes include
conception rate, karyotype of miscarriage, miscarriages (first and second trimester), stillbirths,
pregnancy complications, gestational age at delivery, congenital abnormality and side effects of
steroids. The trial has 2 stages: i) screening of non-pregnant women and ii) randomisation of the
pregnant cohort. All patients who fit the inclusion criteria (<40 years old, ≥3 consecutive
miscarriages with no cause found and no contraindications to prednisolone therapy) will be asked
to consent to an endometrial biopsy in the mid-luteal phase to assess their levels of uNK cells.
Women with high levels of uNK cells (≥5%), will be randomised to either prednisolone or placebo
when a pregnancy is confirmed. Follow-up includes 2 weekly ultrasound scans in the first trimester,
an anomaly scan at 20 weeks gestation, growth scans at 28 and 34 weeks gestation and a postnatal
follow-up at 6 weeks.
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Background
Recurrent miscarriage (RM) is defined as the loss of 3 or
more consecutive pregnancies and is a stressful condition
for both patients and clinicians alike. It affects about 1%
of all fertile couples trying to conceive [1,2]. Despite a
wide range of investigations, no apparent cause is found
in more that 50% of cases and they are categorized as idi-
opathic recurrent miscarriage [2,3]. Apart from supportive
care in a dedicated early pregnancy unit with regular reas-
surance scans and psychological support, empirical treat-
ment in this group of women is not recommended [1,4].
Immunomodulation therapies such as steroids, intrave-
nous immunoglobulin (IVIG), 3rd party donor cell
immunization, paternal cell immunization and trophob-
last membrane infusion have been proposed with con-
flicting evidence as to their efficacies. A meta-analysis of
trials evaluating IVIG, 3rd party donor cell immunization,
paternal cell immunization and trophoblast membrane
infusion found no evidence of a beneficial effect over pla-
cebo in preventing further miscarriages [5]. Porter et al
concluded that "a specific assay to diagnose immune-
mediated early pregnancy loss and a reliable method to
determine which women might benefit from manipula-
tion of the maternal immune system are urgently needed"
[5]. This trial is intended to make progress towards meet-
ing the challenge of diagnosing and treating immune-
mediated early pregnancy loss.
Uterine Natural Killer Cells
The putative association of recurrent miscarriage and
immunological phenomenon has been present for many
years. Natural killer (NK) cells which form part of the
innate immune system are found in peripheral blood and
in the endometrium. Although sharing some similar
properties, peripheral and uterine natural killer (uNK)
cells are unique cell types with distinct antigenic features
and functional markers. UNK cells in peripheral circula-
tion differ in many respects to those in the endometrium
[6-8]. It is the intensity of CD56 antigen expression and
the lack of two typical NK cell markers - CD16 and CD 57
antigens, that differentiate uterine from peripheral NK
cells. Around 80% of uNK cells are CD56bright and CD16-
whereas 90% of peripheral NK cells show opposite char-
acteristics; they are CD56dim and CD16+ [7,9].
Uterine NK cells are the most predominant leucocytes in
the endometrium and their density varies throughout the
menstrual cycle. UNK cell density increases in number
towards the mid-luteal phase and peaks in early preg-
nancy if implantation occurs [8]. UNK cells accumulate as
a dense infiltrate at the implantation site near stromal
cells, glands, blood vessels and trophoblast cells in early
pregnancy [7]. In-vitro studies have also shown that
extravillous trophoblast and uNK cells interaction occurs
[10]. These interactions may have an effect on trophoblast
invasion. However, more recent evidence points to the
role of uNK cells as one of controlling angiogenesis [11].
Embryo implantation and early pregnancy development
occur in a relatively hypoxic environment (2-3% O2) [12].
Inappropriate blood flow to the intervillous space has
been associated with oxidative stress damage to the devel-
oping placenta and thus miscarriage [13]. UNK cell den-
sity in women with recurrent miscarriage was found to be
positively correlated with endometrial angiogenesis and
uterine artery blood flow [14]. A similar positive correla-
tion was also found in women with unexplained recurrent
failure of in-vitro fertilisation (IVF) [15]. Thus, we have
proposed that increased uNK cell density is associated
with increased number of spiral arteries which may lead
to inappropriate blood flow to the developing foetal-pla-
cental unit causing oxidative stress and consequent mis-
carriage [14].
Uterine NK cells and Recurrent Miscarriage
Increased density of uNK cells in pre-implantation
endometrium has been found in women with RM com-
pared to fertile controls [16-19]. However, there are also
studies that have shown no difference in the population
of uNK cells in patients with RM and controls but these
included women with only 2 consecutive miscarriages
[20,21]. Whether high numbers of uNK cells in the mid-
luteal phase predict subsequent miscarriage is controver-
sial. One study suggested that they do [17] but a more
recent slightly larger study refuted this [19]. However,
both studies were small in number and were retrospec-
tively analysed.
Studies on normal and miscarried early pregnancy decid-
uas have also implicated uNK cells in the aetiology of idi-
opathic RM [22,23].
The effect of prednisolone on uNK cells
UNK cells express both glucocorticoid and ER-β receptors
[24]. Thus, therapeutic manipulation of these cells may be
possible. Prednisolone was chosen as the steroid for
manipulation as it is metabolised by the placenta and very
little of the drug reaches the fetus [25]. One woman with
significantly raised uNK cells had 17 miscarriages and was
given 5 mg of prednisolone pre-conceptually. She had a
further 2 miscarriages and then had 20 mgs of pred-
nisolone once a day both pre-conceptually and in early
pregnancy. On this regime, she had a live birth [26].
Next, a prospective study was carried out with 20 mg pred-
nisolone from day 1 to day 21 of the menstrual cycle
which demonstrated a reduction in uNK cells in the pre-
implantation endometrium of patients with idiopathic
RM [18]. This study, carried out in Liverpool investigated
85 women with RM and 18 women with 2 or more nor-Trials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102
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mal pregnancies for uNK cells density via mid-luteal
phase endometrial biopsy. The normal range of uNK cells
was defined using the upper end of the inter-quartile
range for the 18 control women. Thus, women with more
than 5% uNK cells per stromal cell were considered to
have high levels. 32 women with RM had high levels of
uNK cells and 29 agreed to take 20 mg prednisolone for 3
weeks and have a second biopsy. In 23 women, the
number of uNK cells decreased. The reduction in uNK cell
density was significant with a mean level of 14% before
treatment to 9% after treatment (p = 0.0004, CI 2.3-12).
Furthermore, 3 women requested a third biopsy after a
further month of prednisolone and in each case, the uNK
cells level had fallen further suggesting that prolonging
the steroid therapy for longer than 3 weeks further reduces
the level of uNK cells. None of these women reported side
effects significant enough to stop the medication.
Aims of trial
The primary aim of this trial is to investigate whether
prednisolone therapy during the first trimester of preg-
nancy is able to reduce the risk of miscarriage and
improve live birth rates in patients with idiopathic RM
and raised uNK cells in the endometrium.
Primary Outcome
The primary outcome is the number of babies born alive.
Secondary Outcomes
They will include:
- Conception rate
- First and second trimester miscarriages
- Number of losses of empty gestation sacs and foetal
losses
- Karyotype of miscarried pregnancies
- Stillbirths
- Intrauterine growth restriction (IUGR) defined as birth
weight below the 5th centile according to customised birth
weight charts
- Pregnancy complications such as pre-eclampsia or gesta-
tional diabetes
- Gestational age at delivery
- Foetal abnormality
- Side effect of steroids (eg: mood changes, weight gain,
increased appetite, indigestion, avascular necrosis of the
hip, hypertension or hyperglycemia)
Methodology
Design
This will be a randomised, double-blind, placebo control-
led trial with an initial pilot phase to assess feasibility of
recruitment and randomisation. Women are recruited
from Liverpool Women's Hospital's recurrent miscarriage
clinic which is the tertiary referral centre for the region and
an endometrial research clinic. Referrals for the research
clinic are from all over UK and Europe following media
publicity surrounding the publication of the case report
about a successful pregnancy with steroid use after 19 con-
secutive miscarriages [26] and national presentations.
When these women are first seen in the RM clinic, or if a
referral letter to the research clinic is received, patient
information leaflets regarding the trial are given or sent to
them for consideration of their participation in this study
(Figure 1). Women willing to participate are encouraged
to ring for an appointment 6-9 days after their luteinising
hormone (LH) surge in a cycle where they have not tried
to conceive (patient information leaflet advises patients to
get an ovulation kit and to use contraception). At this
appointment, a full history is taken and the results of pre-
vious investigations noted to ensure that there is no cause
found for RM. The trial is then explained further and con-
sent obtained to perform a transvaginal scan and an
endometrial biopsy.
The endometrial biopsy is then taken and the sample
fixed in formalin, processed and embedded in paraffin
wax. 3 μm sections are prepared and stained for CD56
using immunohistochemistry. A positive control slide
from a patient known to have high uNK cells and an IgG
mouse negative control is used for every slide undergoing
immunohistochemistry to ensure no false negative or
false positive staining. Next, 10 high-powered fields from
different areas along the epithelial edge of the sample are
selected and photographed. Then, the glandular epithelial
cells and blood vessel are removed electronically. Subse-
quently, the number of CD56 positive and negative cells
in each field are counted using image analysis software.
Image analysis has markedly reduced the inter-observer
error as compared with manual counting [27]. For each
observer, Bland-Altman plots were produced to ensure
that there were no systematic differences in uNK or stro-
mal cell counts between observers. The inter- and intra-
observer co-efficients of variation were 12.2 (SD 6.53)
and 6.8 (SD 4.29) respectively. The normal range was
defined as <5% uNK cells per stromal cell using the upper
end of the interquartile range of control patients from a
previous study [18]. The positive and negative predictiveTrials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102
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values will be calculated with the results of the trial.
Results of the uNK cell counts are communicated to the
women by letter with a follow up telephone consultation.
Those with normal uNK cell density are advised to follow
standard management. Those with uNK cell counts of
≥5% are advised to contact the research team as soon as
they are pregnant to be considered for randomisation.
Inclusion Criteria
- 3 or more consecutive miscarriages with no cause found
(idiopathic)
- Less than 40 years old
- ≥5% uNK cells at day LH +6 to +9
Exclusion Criteria
- Known cause for recurrent miscarriage: antiphospholi-
pid syndrome (positive anticardiolipin antibody or lupus
anticoagulant on 2 separate occasion at least 6 weeks
apart), thrombophilia (factor V Leiden mutation, APCR
resistance, protein C or S deficiency, prothrombin
G20210A mutation, antithrombin III deficiency), abnor-
mal thyroid function tests, parental balanced transloca-
tion or uterine anomaly (known subseptate uterus or
cervical weakness diagnosed at hysteroscopy).
- Contraindications to steroid therapy: hypertension, dia-
betes, mental health problems or obesity with BMI >35
- Decline consent to randomisation
Randomisation and blinding
Women meeting the inclusion criteria are scanned after a
positive pregnancy test. If a viable intrauterine pregnancy
between 4-8 weeks gestation is found, then a second con-
sent is obtained for randomisation to either prednisolone
or placebo. Once consent if obtained, women are given
consecutive study numbers then sent to pharmacy. A ded-
icated pharmacist then allocates to the treatment or pla-
cebo group the women using her study number. This
study number allocation is performed by using a ran-
domisation list that was pre-constructed with a computer-
ised random number generator in blocks of 20. All
women are given a pack of tablets by the pharmacist and
advised to take 4 tablets for 6 weeks, 2 tablets for 1 week
and 1 tablet for 1 week. Both prednisolone and placebo
tablets are similar in size and colour and dispensed in
identical packaging. The active tablets consist of 5 mgs of
prednisolone and the placebo is an inert substance spe-
cially made to be identical to the placebo. Women are also
given a chart that tells them how many tablets to take each
day and instructions to mark off each day they take the
study medication. They are then asked to return this chart
to the investigators at 14 weeks gestation so that compli-
ance is monitored. Thus, both the trial investigators and
women are blind to the treatment allocation.
Case report forms (CRF) are then completed and given to
an independent research administrator who enters the
information on a database and keeps them as confidential
trial documentation. The research administrator will gen-
erate reports to the data monitoring committee (DMC) as
necessary.
All women participating in the trial are given a trial ID
card where contact details of the hospital are available to
get in touch with either the chief investigator (CI) or prin-
cipal investigator (PI) in the event of an emergency where
the trial group allocation needs to be identified. The CI or
PI will then authorise the pharmacy department to
unblind the group only if severe illness occurs and the
attending physician needs to know whether the women
had been allocated steroids. The DMC will also be able to
unblind these groups if necessary.
Patient flow during trial Figure 1
Patient flow during trial.
Referral letter from GP/Recurrent Miscarriage Clinic 
Patient information leaflet explaining trial sent or given to patient  
            Patient to ring for appointment  
       6-9 days after LH surge if  
       interested to participate  
STEP 1: SCREENING 
   Take history, and review RM investigations 
      If known cause of recurrent miscarriage  
          Ineligible for trial and for usual care                       
If idiopathic recurrent miscarriage (no cause found) 
Explain trial again and consent taken for screening 
                                  Perform endometrial biopsy 
Biopsy analysed in laboratory for uNK cells count 
If uNK <5%          
  Ineligible for trial and for usual care           
,IX1.  
         Advise woman to contact research team when pregnant 
STEP 2: RANDOMISATION 
      Ultrasound scan performed to ensure intrauterine pregnancy  
    2
nd step of trial explained and consent taken for randomisation 
Randomise to either prednisolone or placebo 
   
              2 weekly reassurance  
ultrasound scan and assess 
        side effects (if any) 
   At 12 weeks refer for booking and consultant-led obstetric care 
At 14 weeks collect side effects diary and completed forms 
                Arrange for routine 20 week anomaly scan 
     Arrange for growth scans at 28 and 34 weeks gestation 
Follow up pregnancy outcome data approximately    
               6 weeks after expected due date Trials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102
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Monitoring in pregnancy
After randomisation, women will be offered a 2 weekly
ultrasound scan for reassurance and a clinic consultation
to assess side effects of treatment. This will be done by ask-
ing them about side effects, reviewing the side effect diary,
and measuring the blood pressure until 12 weeks gesta-
tion. If hypertension or any significant side effects
occurred, they will be asked to stop the medication. Any
side effects reported will be assessed in terms of their seri-
ousness, causality and expectedness. If the event was
deemed serious, a serious adverse event or adverse event
(SAE/AE) report form will be completed by the CI or PI
and submitted to the relevant committees. If it was a sus-
pected unexpected serious adverse reaction (SUSAR), then
reporting will be expedited accordingly.
At 12 weeks gestation, women are referred to the hospital
of their choice for booking and consultant-led antenatal
care. At 14 weeks gestation, they are reviewed again and
all the CRF are collected. A routine anomaly scan at 20
weeks gestation and growth scans at 28 and 34 weeks ges-
tation will then be arranged. Another telephone follow-up
consultation will be arranged 6 weeks after the delivery of
the baby to assess the pregnancy and secondary outcomes.
Safety considerations
Prednisolone is commonly used to treat medical condi-
tions in pregnancy and has been given in the first trimester
to women with asthma [28], rheumatoid arthritis [29]
and hyperemesis gravidarum [30] with minimal side
effects. It is metabolised by the placenta to inactive pred-
nisone and thus only about 10% of active drug reaches the
foetus [25]. Although there are concerns of possible com-
plications of intrauterine growth restriction and an associ-
ation with cleft palate from animal studies, more recent
studies, even with postnatal follow-up, have not shown
such complications with prednisolone use [30,31].
Sample size calculation
Preliminary power calculation was based on multiple pre-
sumptions informed by minimal data. The live birth rate
on placebo, is assumed from a previous study where 12
women with >5% uNK cells conceived and 6 subse-
quently miscarried (50%) [17]. We believe an increase in
pregnancy success from 50% to 79% would be clinically
important. At present, there is an 80% pregnancy rate in
the RM clinic in LWH. Thus, to reach statistical signifi-
cance, 68 women will need to be recruited in each group
(80% power, 5% 2-sided alpha). Assuming a 70% accept-
ance rate, we will need to ask 136 women to be ran-
domised. Assuming an 80% conception rate after the
biopsy and a 35% rate of high uNK cells, 694 patients
with idiopathic RM will need to be recruited for endome-
trial biopsies (Figure 2). The current on-going pilot study
can confirm the presumptions made above and provide
more information to perform a definitive power calcula-
tion in the future.
Data Analysis
Data analysis will be performed on an intention to treat
basis using a data analysis plan that will be finalised
before data analysis starts. The outline of the data analysis
plan is as follows.
Power calculation diagram Figure 2
Power calculation diagram.Trials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102
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Data will be cleaned prior to any analysis.
The results of the trial, including patient flow during the
trial, will be reported in accordance with the guidelines
from the CONSORT (Consolidated Standards of Report-
ing Trials) statement [32].
Analysis will proceed in the following steps:
1. Summary statistics for demographic information
relating to the allocation groups will be tabulated. The
data will be examined to determine the extent to
which the treatment and placebo groups are similar.
2. The primary outcome will be assessed. The live birth
rate in each group will be expressed as a risk ratio with
95% Confidence Intervals. Statistical significance will
be calculated using the Fisher's exact test. A signifi-
cance value of p < 0.05 will be considered significant.
3. Secondary outcomes will be assessed. The rates of
miscarriage, type of miscarriage (sac loss or fetal loss),
karyotype of miscarried pregnancies, conception rate,
gestational age at delivery and pregnancy complica-
tions will be tabulated. For dichotomous categorical
variables, risk ratios and 95% Confidence Intervals
will be calculated. For other categorical variables, a
chi-squared test will be performed. For continuous
variables, non-parametric tests will be used
4. Pre-specified subgroup analyses will include com-
parisons of women with primary and secondary recur-
rent miscarriage.
5. Adverse events. All adverse events will be tabulated
according to allocation group.
6. Trial process measures. The following will be tabu-
lated: how women come to know of the trial, the rate
of acceptance for screening and randomisation, pro-
portion of women who screened high for uNK cells
and compliance to medication will be evaluated.
Trial Management and Monitoring Structure
Ethical and Regulatory Issues
Approval to conduct the trial has been granted from the
Liverpool Local Research Ethics Committee.
The trial is included on the National Institute for Health
Research (NIHR) Clinical Research Portfolio (NIHR CRN
ID: 6567) and is registered with European and interna-
tional clinical trials database (EUDRACT No: 2005-
003307-36, ISRCTN28090716). MHRA approval was also
granted.
Patient Acceptability and Consent
The trial has been discussed with the President of the Mis-
carriage Association, as the patient representative. We
were advised that women who have had recurrent miscar-
riages would be suitable to be randomised to a placebo.
The Miscarriage Association have also agreed to be inde-
pendent advisors to women during the recruitment phase
and throughout the trial. Additionally, women are
informed that if a miscarriage occurred while they are on
the trial, they can choose to have prednisolone in the sub-
sequent pregnancy with the understanding that this is yet
to be proven as an effective treatment.
Women who fit the inclusion criteria will be informed
about the objectives of the study and be given written
information about it. They will then have time to consider
the trial and contact the investigators for a consultation
appointment when they ovulate if interested to partici-
pate. Consent will be obtained by the trial investigators
prior to screening for levels of uNK cells. A separate con-
sent for randomisation into the study is taken when the
woman is found to have raised uNK cells and is pregnant.
Data Monitoring Committee (DMC)
A data monitoring committee (DMC) independent of the
trial investigators has been appointed for the trial to pro-
vide independent review of unblinded data at agreed
intervals to ensure that no harm is being cause by the
treatment. The first DMC meeting will be planned for after
20 patients have been randomised into the trial and
passed 14 weeks gestation. Particular emphasis will be
placed upon monitoring the side effect of steroids, fertility
rate and pregnancy complications.
This committee will also address issues such as:
- Significant problems with trial design or methodology
- Recruitment rate
- Patient's acceptance of the possibility of randomisation
to placebo
The chair of the DMC will report to the Trial Steering
Committee (TSC) approximately 2 weeks after each meet-
ing in accordance with recommended trial oversight.
Steering and Management Committees
A trial steering committee (TSC) and trial management
group (TMG) have been formed to supervise and manage
the trial. The TSC will be responsible for approving the
core protocol and any subsequent amendments. The TMG
will meet every 4-6 months to discuss:
- the recruitment rate and patient acceptability of the trialTrials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102
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- side effect of steroids
- data collection forms
- potential problems arising from the trial
The TMG will report the above and present any possible
solutions to problems or strategies to improve recruit-
ment to the TSC who will meet when deemed necessary
by the Chief Investigator.
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